Andrea Pennati
YOU?
Author Swipe
View article: Gαz-independent and -dependent Improvements With EPA Supplementation on the Early Type 1 Diabetes Phenotype of NOD Mice
Gαz-independent and -dependent Improvements With EPA Supplementation on the Early Type 1 Diabetes Phenotype of NOD Mice Open
Prostaglandin E2 (PGE2) is a key mediator of inflammation and is derived from the omega-6 polyunsaturated fatty acid, arachidonic acid (AA). In the β-cell, the PGE2 receptor, Prostaglandin EP3 receptor (EP3), is coupled to the unique heter…
View article: Contents
Contents Open
View article: Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients – A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia
Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients – A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia Open
View article: 383 Radiotherapy, tumor-specific antibodies, and autologous NK/Macrophage cell therapy enhance anti-tumor immunity in metastatic pancreatic cancer
383 Radiotherapy, tumor-specific antibodies, and autologous NK/Macrophage cell therapy enhance anti-tumor immunity in metastatic pancreatic cancer Open
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and metastatic cancer. Despite the potential of cancer immunotherapy, PDAC is one of the least responsive solid tumors. In our previous studies, we have shown that NK ce…
View article: Supplementary Figure Legends from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Supplementary Figure Legends from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
Legends for Supplementary Figures S1-S5.
View article: Data from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Data from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
The clinical efficacy of immune cytokines used for cancer therapy is hampered by elements of the immunosuppressive tumor microenvironment such as TGFβ. Here we demonstrate that FIST15, a recombinant chimeric protein composed of the T-cell–…
View article: Data from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Data from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
The clinical efficacy of immune cytokines used for cancer therapy is hampered by elements of the immunosuppressive tumor microenvironment such as TGFβ. Here we demonstrate that FIST15, a recombinant chimeric protein composed of the T-cell–…
View article: Supplementary Figures S1-S5 from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Supplementary Figures S1-S5 from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
FIST15 treatment increases the proportion of CD8+ T cells NK cells without inducing proliferation of CD4+ T cells or B cells in vitro (S1); MHC-I Expression on B16 and MC-38 tumor cell lines (S2); FIST15 treatment promotes CD8+ memory phen…
View article: Supplementary Figures S1-S5 from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Supplementary Figures S1-S5 from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
FIST15 treatment increases the proportion of CD8+ T cells NK cells without inducing proliferation of CD4+ T cells or B cells in vitro (S1); MHC-I Expression on B16 and MC-38 tumor cell lines (S2); FIST15 treatment promotes CD8+ memory phen…
View article: Supplementary Figure Legends from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein
Supplementary Figure Legends from Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein Open
Legends for Supplementary Figures S1-S5.
View article: Supplementary Figure 3 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 3 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 97K, GIFT4 induces the expansion of murine GM-CSF+ IRA-like cells.
View article: Supplementary Figure 2 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 2 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 79K, Secretome of murine GIFT4-B cells.
View article: Supplementary Figure 6 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 6 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 161K, human GIFT4 induces B-cell mediated anti-melanoma T cell response.
View article: Supplementary Figure 2 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 2 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 79K, Secretome of murine GIFT4-B cells.
View article: Data from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Data from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
Engineered chimeric cytokines can generate gain-of-function activity in immune cells. Here, we report potent antitumor activity for a novel fusion cytokine generated by N-terminal coupling of GM-CSF to IL4, generating a fusokine termed GIF…
View article: Supplementary Figure 5 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 5 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 98K, B6 mice treated with GIFT4 protein or implanted with B16-GIFT4 cells do not produce anti-GIFT4 antibodies.
View article: Supplementary Figure 3 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 3 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 97K, GIFT4 induces the expansion of murine GM-CSF+ IRA-like cells.
View article: Supplementary Figure 6 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 6 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 161K, human GIFT4 induces B-cell mediated anti-melanoma T cell response.
View article: Supplementary Figure 1 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 1 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 134K, GIFT4 induces the proliferation of murine splenocytes.
View article: Supplementary Figure 1 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 1 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 134K, GIFT4 induces the proliferation of murine splenocytes.
View article: Data from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Data from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
Engineered chimeric cytokines can generate gain-of-function activity in immune cells. Here, we report potent antitumor activity for a novel fusion cytokine generated by N-terminal coupling of GM-CSF to IL4, generating a fusokine termed GIF…
View article: Supplementary Figure 4 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 4 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 27K, Murine GIFT4-B cells enhance T-cell IFN-γ production.
View article: Supplementary Figure 5 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 5 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 98K, B6 mice treated with GIFT4 protein or implanted with B16-GIFT4 cells do not produce anti-GIFT4 antibodies.
View article: Supplementary Figure 4 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Supplementary Figure 4 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response Open
PDF file - 27K, Murine GIFT4-B cells enhance T-cell IFN-γ production.
View article: A Pilot Study to Assess the Salivary Gland Regenerative Potential of Bone Marrow Mesenchymal Stromal Cells from Treated Head and Neck Cancer Patients
A Pilot Study to Assess the Salivary Gland Regenerative Potential of Bone Marrow Mesenchymal Stromal Cells from Treated Head and Neck Cancer Patients Open
Background: Salivary dysfunction is a significant side effect of radiation therapy for head and neck cancer (HNC). Preliminary data suggests that mesenchymal stromal cells (MSCs) can improve salivary function. Whether MSCs from HNC patient…
View article: Independent mechanisms underlie the protective effect of dietary polyunsaturated fatty acid supplementation and Gα<sub>z</sub>deficiency on the early type 1 diabetes phenotype of Non-obese diabetic (NOD) mice
Independent mechanisms underlie the protective effect of dietary polyunsaturated fatty acid supplementation and Gα<sub>z</sub>deficiency on the early type 1 diabetes phenotype of Non-obese diabetic (NOD) mice Open
Non-obese diabetic (NOD) mice deficient in G z alpha subunit (Gα z ) are protected from developing hyperglycemia, even with early islet insulitis similar to wild-type mice. Similarly, wild-type (WT) NOD mice are protected from glucose into…
View article: Minor salivary gland mesenchymal stromal cells derived from patients with Sjӧgren's syndrome deploy intact immune plasticity
Minor salivary gland mesenchymal stromal cells derived from patients with Sjӧgren's syndrome deploy intact immune plasticity Open
View article: Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination
Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination Open
The unmet medical need of patients with multiple sclerosis (MS) is the inexorable loss of CNS myelin and latterly neurons leading to permanent neurologic disability. Solicitation of endogenous oligodendrocytes progenitor cells, the precurs…
View article: Isolation and identification of cancer stem cells byALDH activity assay v1
Isolation and identification of cancer stem cells byALDH activity assay v1 Open
Cancer stem cells (CSCs) are a small subpopulation of tumor cells that are thought to be responsible for recurrence and metastasis of cancer due to their ability for self-renewal and differentiation into multiple cancer cell types. Multipl…
View article: Adoptive transfer of IL-10+ regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model
Adoptive transfer of IL-10+ regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model Open